Literature DB >> 28333387

Pathophysiological Fundamentals of Diabetic Cardiomyopathy.

Xinyue Hu1,2, Tao Bai1,2, Zheng Xu1,2, Qiuju Liu3, Yang Zheng1, Lu Cai2,4.   

Abstract

Diabetic cardiomyopathy (DCM) was first recognized more than four decades ago and occurred independent of cardiovascular diseases or hypertension in both type 1 and type 2 diabetic patients. The exact mechanisms underlying this disease remain incompletely understood. Several pathophysiological bases responsible for DCM have been proposed, including the presence of hyperglycemia, nonenzymatic glycosylation of large molecules (e.g., proteins), energy metabolic disturbance, mitochondrial damage and dysfunction, impaired calcium handling, reactive oxygen species formation, inflammation, cardiac cell death, and cardiac hypertrophy and fibrosis, leading to impairment of cardiac contractile functions. Increasing evidence also indicates the phenomenon called "metabolic memory" for diabetes-induced cardiovascular complications, for which epigenetic modulation seemed to play an important role, suggesting that the aforementioned pathogenic bases may be regulated by epigenetic modification. Therefore, this review aims at briefly summarizing the current understanding of the pathophysiological bases for DCM. Although how epigenetic mechanisms play a role remains incompletely understood now, extensive clinical and experimental studies have implicated its importance in regulating the cardiac responses to diabetes, which are believed to shed insight into understanding of the pathophysiological and epigenetic mechanisms for the development of DCM and its possible prevention and/or therapy. © 2017 American Physiological Society. Compr Physiol 7:693-711, 2017.
Copyright © 2017 John Wiley & Sons, Inc.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28333387     DOI: 10.1002/cphy.c160021

Source DB:  PubMed          Journal:  Compr Physiol        ISSN: 2040-4603            Impact factor:   9.090


  37 in total

1.  Activation of adenosine A2b receptor attenuates high glucose-induced apoptosis in H9C2 cells via PI3K/Akt signaling.

Authors:  Yi Shen; Gang Tang; Pan Gao; Bin Zhang; Hang Xiao; Liang-Yi Si
Journal:  In Vitro Cell Dev Biol Anim       Date:  2018-04-06       Impact factor: 2.416

2.  Docosahexaenoic acid lowers cardiac mitochondrial enzyme activity by replacing linoleic acid in the phospholipidome.

Authors:  E Madison Sullivan; Edward Ross Pennington; Genevieve C Sparagna; Maria J Torres; P Darrell Neufer; Mitchel Harris; James Washington; Ethan J Anderson; Tonya N Zeczycki; David A Brown; Saame Raza Shaikh
Journal:  J Biol Chem       Date:  2017-11-21       Impact factor: 5.157

3.  Hydrogen sulfide mitigates myocardial inflammation by inhibiting nucleotide-binding oligomerization domain-like receptor protein 3 inflammasome activation in diabetic rats.

Authors:  Qiang Jia; Shomaila Mehmood; Xiaofen Liu; Shanfeng Ma; Rui Yang
Journal:  Exp Biol Med (Maywood)       Date:  2020-01-13

4.  Silencing lncRNA GAS5 alleviates apoptosis and fibrosis in diabetic cardiomyopathy by targeting miR-26a/b-5p.

Authors:  Chunping Zhu; Haijun Zhang; Dongmei Wei; Zhe Sun
Journal:  Acta Diabetol       Date:  2021-06-06       Impact factor: 4.280

5.  Improvement of cardiac ventricular function by magnesium treatment in chronic streptozotocin-induced diabetic rat heart.

Authors:  Hamida Aboalgasm; Morea Petersen; Asfree Gwanyanya
Journal:  Cardiovasc J Afr       Date:  2020-12-10       Impact factor: 1.167

6.  Guan Xin Dan Shen formulation protects db/db mice against diabetic cardiomyopathy via activation of Nrf2 signaling.

Authors:  Bin Zhang; Chen-Yang Zhang; Xue-Lian Zhang; Gui-Bo Sun; Xiao-Bo Sun
Journal:  Mol Med Rep       Date:  2021-05-26       Impact factor: 2.952

7.  Pyridostigmine Protects Against Diabetic Cardiomyopathy by Regulating Vagal Activity, Gut Microbiota, and Branched-Chain Amino Acid Catabolism in Diabetic Mice.

Authors:  Yang Yang; Ming Zhao; Xi He; Qing Wu; Dong-Ling Li; Wei-Jin Zang
Journal:  Front Pharmacol       Date:  2021-05-18       Impact factor: 5.810

8.  miR-503 Is Involved in the Protective Effect of Phase II Enzyme Inducer (CPDT) in Diabetic Cardiomyopathy via Nrf2/ARE Signaling Pathway.

Authors:  Ying Miao; Qin Wan; Xiaoyu Liu; Yu Wang; Yi Luo; Dan Liu; Nengbo Lin; Honggang Zhou; Jiyuan Zhong
Journal:  Biomed Res Int       Date:  2017-12-18       Impact factor: 3.411

9.  Effect of genistein on myocardial fibrosis in diabetic rats and its mechanism.

Authors:  Rui Yang; Qiang Jia; Xiao-Fen Liu; Shan-Feng Ma
Journal:  Mol Med Rep       Date:  2017-12-12       Impact factor: 2.952

Review 10.  The Diabetic Cardiomyopathy: The Contributing Pathophysiological Mechanisms.

Authors:  Teresa Salvatore; Pia Clara Pafundi; Raffaele Galiero; Gaetana Albanese; Anna Di Martino; Alfredo Caturano; Erica Vetrano; Luca Rinaldi; Ferdinando Carlo Sasso
Journal:  Front Med (Lausanne)       Date:  2021-06-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.